MorphoSys AG (MOR)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
As of 03:39PM EDT. Market open.
| Previous Close | 18.13 |
| Open | 18.11 |
| Bid | 18.02 x 200 |
| Ask | 18.04 x 100 |
| Day's Range | 18.02 - 18.11 |
| 52 Week Range | 4.18 - 18.31 |
| Volume | |
| Avg. Volume | 1,796,793 |
| Market Cap | 2.72B |
| Beta (5Y Monthly) | 0.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.48 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.46 |
ACCESSWIREMorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 24, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new efficacy and safety ...
ZacksNovartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
- Zacks
Novartis (NVS) to Undertake Job Cuts in Development Department
Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.
© 2024 Yahoo. All rights reserved.